Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

根据最新的SEC文件显示，Akero Therapeutics Inc. (NASDAQ: AKRO )的首席科学官Rolph Timothy近期进行了一笔重要的股票交易。值得注意的是，根据 InvestingPro ...

旧金山讯—根据最新的SEC文件显示，Akero Therapeutics, Inc. (NASDAQ: AKRO )董事Graham G. Walmsley于1月30日以每股48美元的价格购入了200,000股公司普通股，总价值960万美元。该公司股票在过去一年上涨了191%，目前交易价格为54.21美元，已为这位董事的投资带来可观收益。 InvestingPro ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...